$831 Million is the total value of Fairmount Funds Management LLC's 20 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 150.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | APOGEE THERAPEUTICS INC | $62,647,049 | – | 2,941,176 | +100.0% | 7.54% | – | |
| MRUS | Buy | MERUS N V | $44,362,115 | +13.7% | 1,881,345 | +26.9% | 5.34% | -3.0% |
| KNSA | Buy | KINIKSA PHARMACEUTICALS LTD | $42,983,125 | +333.4% | 2,474,561 | +251.3% | 5.17% | +269.9% |
| ARGX | Buy | ARGENX SEsponsored adr | $41,172,538 | +43.7% | 83,747 | +13.9% | 4.95% | +22.6% |
| New | SOLENO THERAPEUTICS INC | $33,714,378 | – | 1,142,473 | +100.0% | 4.06% | – | |
| Buy | ENLIVEN THERAPEUTICS INC | $29,114,501 | -32.9% | 2,131,369 | +0.3% | 3.50% | -42.7% | |
| IMVT | New | IMMUNOVANT INC | $28,792,500 | – | 750,000 | +100.0% | 3.46% | – |
| New | RAYZEBIO INC | $27,126,269 | – | 1,221,904 | +100.0% | 3.26% | – | |
| New | DIANTHUS THERAPEUTICS INC | $26,362,636 | – | 1,928,503 | +100.0% | 3.17% | – | |
| New | AEGLEA BIOTHERAPEUTICS INC | $4,635,657 | – | 378,421 | +100.0% | 0.56% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.